Patients on Optune experienced fewer systemic AEs than patients on chemotherapy alone1


*Thrombocytopenia from prior chemotherapy, normalized subsequently.
- The most common (≥10%) AEs seen with Optune monotherapy were medical device site reaction and headache3
- The following AEs were considered related to Optune: medical device site reaction, headache, malaise, muscle twitching, fall, and skin ulcer2
- In EF-11, 16% of patients experienced a grade 1/2 medical device site reaction2
- Mild-to-moderate skin irritation, the most common device-related side effect with Optune, was typically manageable, reversible, and did not result in treatment discontinuation2
Improved safety vs chemotherapy1
- Significantly fewer of the systemic AEs associated with chemotherapy, including gastrointestinal side effects, hematological side effects, and infections, were observed with Optune
AEs, adverse events; GBM, glioblastoma.
- Optune. Instructions for Use for Glioblastoma Multiforme. Novocure; 2019.
- Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192-2202.
- Novocure Data on File OPT-109.